The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.
Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.
Almost all ophthalmic medications contain preservatives, which inhibit bacterial growth. The use of preservatives allows for the use of multidose bottles, which are the most cost-effective and user-friendly packaging for ophthalmic medications. However, some of the preservatives present in commonly used eye drops today have been shown to be disruptive to the cornea surface.1-5